These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 21592479)

  • 1. Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis.
    Lee M; Saver JL; Towfighi A; Chow J; Ovbiagele B
    Atherosclerosis; 2011 Aug; 217(2):492-8. PubMed ID: 21592479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction.
    Tenenbaum A; Fisman EZ
    Cardiovasc Diabetol; 2012 Oct; 11():125. PubMed ID: 23057687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. "If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.
    Tenenbaum A; Fisman EZ
    Cardiovasc Diabetol; 2010 Jun; 9():24. PubMed ID: 20550659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis.
    Bruckert E; Labreuche J; Deplanque D; Touboul PJ; Amarenco P
    J Cardiovasc Pharmacol; 2011 Feb; 57(2):267-72. PubMed ID: 21052016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of fibrates on lowering low-density lipoprotein cholesterol and cardiovascular risk reduction: a systemic review and meta-analysis.
    Kim KA; Kim NJ; Choo EH
    Eur J Prev Cardiol; 2024 Feb; 31(3):291-301. PubMed ID: 37855457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrates in the management of atherogenic dyslipidemia.
    Okopień B; Buldak L; Bołdys A
    Expert Rev Cardiovasc Ther; 2017 Dec; 15(12):913-921. PubMed ID: 29183206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do persons with diabetes benefit from combination statin and fibrate therapy?
    Rosenblit PD
    Curr Cardiol Rep; 2012 Feb; 14(1):112-24. PubMed ID: 22213157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrate therapy and flow-mediated dilation: A systematic review and meta-analysis of randomized placebo-controlled trials.
    Sahebkar A; Giua R; Pedone C; Ray KK; Vallejo-Vaz AJ; Costanzo L
    Pharmacol Res; 2016 Sep; 111():163-179. PubMed ID: 27320045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of fibrate treatment in dyslipidemia: an overview.
    Katsiki N; Nikolic D; Montalto G; Banach M; Mikhailidis DP; Rizzo M
    Curr Pharm Des; 2013; 19(17):3124-31. PubMed ID: 23317397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study.
    Halcox JP; Banegas JR; Roy C; Dallongeville J; De Backer G; Guallar E; Perk J; Hajage D; Henriksson KM; Borghi C
    BMC Cardiovasc Disord; 2017 Jun; 17(1):160. PubMed ID: 28623902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefits and risks of the treatment with fibrates--a comprehensive summary.
    Okopień B; Bułdak Ł; Bołdys A
    Expert Rev Clin Pharmacol; 2018 Nov; 11(11):1099-1112. PubMed ID: 30328735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of fibrate therapy on plasma plasminogen activator inhibitor-1: a systematic review and meta-analysis of randomized controlled trials.
    Sahebkar A; Simental-Mendía LE; Watts GF; Golledge J
    Atherosclerosis; 2015 May; 240(1):284-96. PubMed ID: 25828270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Therapeutic targets in the treatment of dyslipidemia: HDL and non-HDL cholesterol].
    Brea Hernando ÁJ
    Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():3-6. PubMed ID: 25043539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do lipids and apolipoproteins predict coronary heart disease under statin and fibrate therapy in the primary prevention setting in community-dwelling elderly subjects? The 3C Study.
    Straczek C; Tafflet M; Barberger-Gateau P; Bertrand M; Dupuy AM; Ducimetière P; Empana JP
    Atherosclerosis; 2011 Feb; 214(2):426-31. PubMed ID: 21129746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of high-density lipoprotein targeting treatments on cardiovascular outcomes: A systematic review and meta-analysis.
    Riaz H; Khan SU; Rahman H; Shah NP; Kaluski E; Lincoff AM; Nissen SE
    Eur J Prev Cardiol; 2019 Mar; 26(5):533-543. PubMed ID: 30861690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of fibrate-statin combination therapy compared to fibrate monotherapy in patients with dyslipidemia: a meta-analysis.
    Choi HD; Shin WG; Lee JY; Kang BC
    Vascul Pharmacol; 2015; 65-66():23-30. PubMed ID: 25451563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Fibrates therapy: Rational use fenofibrate 2016. Executive summary].
    Brea A; Millán J; Ascaso JF; Blasco M; Díaz A; González-Santos P; Hernández-Mijares A; Mantilla T; Pedro-Botet JC; Pintó X;
    Clin Investig Arterioscler; 2016; 28(6):295-301. PubMed ID: 27609708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significant increase in high-density lipoprotein cholesterol with fibrates is associated with low pretreatment high-density lipoprotein cholesterol: findings from an outpatient clinic setting.
    Ramachandran S; Abbas A; Saraf S; Raju J; Jewkes C; Jones AF
    Metab Syndr Relat Disord; 2012 Jun; 10(3):189-94. PubMed ID: 22283634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal pharmacotherapy to combat the atherogenic lipid triad.
    Chapman MJ; Redfern JS; McGovern ME; Giral P
    Curr Opin Cardiol; 2011 Sep; 26(5):403-11. PubMed ID: 21730827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management.
    Chapman MJ; Ginsberg HN; Amarenco P; Andreotti F; Borén J; Catapano AL; Descamps OS; Fisher E; Kovanen PT; Kuivenhoven JA; Lesnik P; Masana L; Nordestgaard BG; Ray KK; Reiner Z; Taskinen MR; Tokgözoglu L; Tybjærg-Hansen A; Watts GF;
    Eur Heart J; 2011 Jun; 32(11):1345-61. PubMed ID: 21531743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.